NETSCOUT SYSTEMS, INC. , a leading provider of enterprise performance management, carrier service assurance, cybersecurity, and DDoS protection solutions, announced today that the Company plans to ...

Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in May. Chief Executive Officer Kyle Gano ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Tempus AI, Inc. Class A (($TEM)) has held its Q1 earnings call. Read on for the main highlights of the call. Tempus AI, Inc. Class A recently held ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence (AI) to healthcare, has announced strategic collaborations with pharmaceutical giant AstraZeneca (LSE/STO ...